Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies
Status:
ENROLLING_BY_INVITATION
Trial end date:
2026-06-14
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate the efficacy and safety of desmopressin to prevent bleeding after percutaneous renal graft biopsy in patients at high risk of bleeding.
Researchers will compare desmopressin (DDAVP) to placebo to see if the drug reduces the risk of bleeding events related to kidney biopsy.
Participants will receive intravenous desmopressin medication (100ml) or placebo (100mL of saline solution) before the kidney biopsy.